178 related articles for article (PubMed ID: 30606771)
21. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
22. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
23. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
24. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ
Elife; 2016 Jan; 5():. PubMed ID: 26731516
[TBL] [Abstract][Full Text] [Related]
25. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
Tillinghast GW; Partee J; Albert P; Kelley JM; Burtow KH; Kelly K
Genes Chromosomes Cancer; 2003 Jun; 37(2):121-31. PubMed ID: 12696060
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
[TBL] [Abstract][Full Text] [Related]
27. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
[No Abstract] [Full Text] [Related]
28. Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells.
Hall RE; Tilley WD; McPhaul MJ; Sutherland RL
Int J Cancer; 1992 Nov; 52(5):778-84. PubMed ID: 1428232
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
30. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
31. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
32. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.
Shendy NAM; Bikowitz M; Sigua LH; Zhang Y; Mercier A; Khashana Y; Nance S; Liu Q; Delahunty IM; Robinson S; Goel V; Rees MG; Ronan MA; Wang T; Kocak M; Roth JA; Wang Y; Freeman BB; Orr BA; Abraham BJ; Roussel MF; Schonbrunn E; Qi J; Durbin AD
Nat Commun; 2024 Apr; 15(1):3483. PubMed ID: 38664416
[TBL] [Abstract][Full Text] [Related]
33. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
34. Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors.
Mitra S; Dash R
J Mol Graph Model; 2018 Aug; 83():42-52. PubMed ID: 29758466
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel JM; Birrell SN; Pickering MA; Holds DJ; Horsfall DJ; Tilley WD
Mol Cell Endocrinol; 1999 Aug; 154(1-2):11-20. PubMed ID: 10509795
[TBL] [Abstract][Full Text] [Related]
36. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
Yeap BB; Krueger RG; Leedman PJ
Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
[TBL] [Abstract][Full Text] [Related]
37. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression.
Hall RE; Birrell SN; Tilley WD; Sutherland RL
Eur J Cancer; 1994; 30A(4):484-90. PubMed ID: 8018407
[TBL] [Abstract][Full Text] [Related]
38. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
39. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
40. The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics.
Tahtamouni L; Alzghoul A; Alderfer S; Sun J; Ahram M; Prasad A; Bamburg J
PLoS One; 2022; 17(12):e0279746. PubMed ID: 36584207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]